GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Mounjaro vs Wegovy in India — Which Loses More Weight?

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) are the two highest-efficacy weight-loss injectables available in India. Mounjaro is a dual GIP/GLP-1 receptor agonist that produces ~22.5% body weight reduction at 15 mg over 72 weeks (SURMOUNT-1). Wegovy is a pure GLP-1 agonist producing ~14.9% at 2.4 mg over 68 weeks (STEP-1). Mounjaro generally wins on raw efficacy; Wegovy has longer real-world safety data.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Mounjaro vs Wegovy — at a glance

AttributeMounjaroWegovy
Active ingredientTirzepatide (dual GIP/GLP-1)Semaglutide (GLP-1 only)
Indication (India)Type 2 Diabetes + ObesityObesity / Chronic Weight Management
DCGI approvalMarch 20252025–2026
Dose strengths2.5, 5, 7.5, 10, 12.5, 15 mg weekly0.25, 0.5, 1, 1.7, 2.4 mg weekly
Maintenance dose5–15 mg weekly2.4 mg weekly
Form factorKwikPen pre-filled / single-dose vialPre-filled pen
FrequencyOnce weeklyOnce weekly
Approx. monthly price (India, 2026)₹14,000 – ₹27,500₹5,660 – ₹16,400
Mean weight loss (pivotal trial)~22.5% at 15 mg (SURMOUNT-1, 72 wk)~14.9% at 2.4 mg (STEP-1, 68 wk)
Patients reaching ≥15% loss~63% on 10 mg, ~78% on 15 mg~50% on 2.4 mg
Real-world experience (years)~2 years globally; <1 year in India~3 years globally; ~1 year in India
Prescription requiredYes (Schedule H)Yes (Schedule H)

Efficacy — what the trials show

Mounjaro

Mounjaro’s pivotal weight-loss data comes from the SURMOUNT program. SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) without T2D. Mean weight loss at 72 weeks: 16% on 5 mg, 21.4% on 10 mg, 22.5% on 15 mg, vs 2.4% on placebo. SURMOUNT-2 extended the data to T2D patients. SURMOUNT-3 showed continued loss when patients had already lost 6.9% via lifestyle alone. The dual mechanism — activating both GIP and GLP-1 receptors — appears to drive the efficacy gap over single-agonist drugs.

Wegovy

Wegovy’s STEP-1 trial (NEJM 2021): mean 14.9% body weight loss over 68 weeks on 2.4 mg, vs 2.4% on placebo. STEP-2 (patients with T2D): 9.6% loss. STEP-UP (Wegovy HD at 7.2 mg, 2026 data) is pushing efficacy closer to Mounjaro’s range but isn’t DCGI-approved in India yet. SELECT trial: 20% MACE reduction in patients with established cardiovascular disease — this is Wegovy’s differentiating cardiovascular data point.

Cost in India (2026)

Mounjaro

Mounjaro is the most expensive GLP-1 option in India: ₹14,000–27,500/month. The 15 mg target dose costs roughly ₹25,000–27,500 in private pharmacies. Pricing scales steeply with dose, unlike most generics. Insurance coverage is rare. Eli Lilly’s patient access program in India is not yet widely available.

Wegovy

Wegovy in India: ₹5,660–16,400/month, scaling with dose. The 2.4 mg maintenance dose runs around ₹12,000–16,400. Indian generic semaglutides (Sundae, Noveltreat, Obeda) are available at ₹1,290–3,000 for the same molecule at a comparable dose, though not at all dose strengths.

Side effects

Mounjaro

Mounjaro’s GI side-effect profile is similar to but generally milder than semaglutide. In SURMOUNT-1: nausea in 28% (vs 44% in STEP-1), diarrhea in 23%, vomiting in 13%. Discontinuation due to adverse events: 4.5–7.1% depending on dose. Long-term GIP-receptor effects in humans are less well-characterized than GLP-1 alone, though no major safety signals have emerged in the ~2 years of broad use.

Wegovy

Wegovy: nausea 44%, diarrhea 32%, vomiting 25% in STEP-1, peaking during titration. The longer real-world experience with semaglutide means rare events (pancreatitis, gallbladder disease, thyroid C-cell tumour signal) are better characterized. Indian endocrinologists have ~3 years of clinical experience with the molecule.

Which one should you consider?

Pick Mounjaro if

  • ✓You want maximum non-surgical weight loss
  • ✓You have T2D where the dual agonist mechanism may help glucose control more
  • ✓Cost is not a primary constraint
  • ✓You’ve already tried single-agonist GLP-1 (Ozempic or Wegovy) without sufficient effect

Pick Wegovy if

  • ✓You want a longer-track-record molecule
  • ✓You have established cardiovascular disease (SELECT trial benefit)
  • ✓You are price-sensitive and may downshift to an Indian generic
  • ✓Your doctor is more comfortable with semaglutide

Frequently asked questions

Is Mounjaro really better than Wegovy for weight loss?+
On average, yes — SURMOUNT-1 produced ~22.5% mean weight loss at 15 mg, versus Wegovy’s ~14.9% in STEP-1. But individual response varies. About 30–40% of Mounjaro patients lose 25%+ of body weight; about 50% of Wegovy patients lose ≥15%. If you don’t respond well to one class, switching is reasonable. Mounjaro’s additional GIP-receptor activation appears to be the mechanism behind the efficacy gap.
Why is Mounjaro so much more expensive than Wegovy in India?+
Mounjaro’s production cost is higher (a more complex dual-agonist molecule) and Eli Lilly priced the India launch (March 2025) at a premium relative to Wegovy. Indian generics of tirzepatide are not yet available — when they arrive (likely 2027–2028 post-patent), prices will drop significantly, mirroring the semaglutide generics market today.
Can I switch from Wegovy to Mounjaro if I plateau?+
Yes. About 15–20% of Wegovy users plateau before reaching their goal, and switching to Mounjaro is a common next step. The switch isn’t a 1:1 dose match; your doctor will typically restart at a low Mounjaro dose (2.5 or 5 mg) and re-titrate over 4–8 weeks. Don’t self-switch — overlap dosing or stopping Wegovy abruptly can cause GI symptoms and weight rebound.
Are the side effects of Mounjaro worse than Wegovy?+
In trials, Mounjaro’s GI side effects were slightly LESS severe than Wegovy’s, despite the higher efficacy. SURMOUNT-1: nausea 28%, vs STEP-1: nausea 44%. The dual GIP/GLP-1 mechanism may temper some GLP-1-driven nausea. That said, real-world experience varies widely by patient.
Does Mounjaro work for patients without diabetes in India?+
Yes — Mounjaro is DCGI-approved for both obesity (chronic weight management) and type 2 diabetes in India. The SURMOUNT-1 trial specifically enrolled adults with obesity and no T2D, and that’s its weight-loss approval basis. You don’t need diabetes to qualify for Mounjaro, but your doctor must document the BMI/comorbidity rationale per Indian obesity guidelines.
Is there an Indian generic version of Mounjaro?+
Not as of mid-2026. The Mounjaro (tirzepatide) molecule is under patent in India for several more years; only Eli Lilly’s branded version is available. By contrast, semaglutide (Wegovy/Ozempic) has 10+ Indian generic brands available now. If cost is a major factor, semaglutide generics are an option Mounjaro doesn’t yet have an equivalent for.
Will I keep the weight off after stopping Mounjaro or Wegovy?+
Both molecules have similar weight-regain patterns. SURMOUNT-4 and STEP-4 trials both show 60–70% of lost weight returns within 12 months of discontinuation. The long-term play is usually continued (lower-dose) therapy combined with structural lifestyle changes during the treatment window.

Related comparisons

Ozempic vs Mounjaro

Ozempic vs Mounjaro in India — For Diabetes and Weight

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.